Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications

    Contains 7 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications presented at The Liver Meeting® 2018.

    This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.

    Jessica Zucman-Rossi

    Augusto Villanueva

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

    Josep Llovet

    Anthony El-Khoueiry

    Richard Finn

  • Hepatology Associates Course

    Product not yet rated Contains 12 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatology Associates Course presented at The Liver Meeting® 2018.

    This half-day program provides an overview of both current and emerging therapies for common liver diseases. Additionally, it will enhance knowledge around diagnostics and highlight the roles of collaborating professionals.

    Yuko Kono

    John E. Eaton

    Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr. Eaton’s research focus is the conduction of clinical trials and the discovery of novel biomarkers (including magnetic resonance imaging technologies) that can predict disease outcomes.

    Anne Croghan

    Robert S. Rahimi

    Romil Saxena

    Robert J. Fontana

    Jasmohan S. Bajaj

  • Hepatology Associates SIG: Avoiding Common Pitfalls in Cirrhosis Management

    Product not yet rated Contains 7 Component(s) Recorded On: 11/11/2018

    AASLD's Hepatology Associates SIG: Avoiding Common Pitfalls in Cirrhosis Management presented at The Liver Meeting® 2018.

    This program has been designed to improve the diagnosis, pharmacologic treatment and management of patients with chronic liver disease. The current data is highlighted to support effective and efficient patient-centered care. Attendees will gain the ability to utilize medical knowledge and research to provide quality, evidence-based care and to enhance interdisciplinary collaboration to improve health outcomes.

    Lisa M. Richards

    Tiffany E. Kaiser

    Carolyn J. Driscoll

    HoChong Gilles

    HoChong Gilles is a board-certified Nurse Practitioner and has been working in the hepatology field since 2001. She obtained a BS in Biology and Master’s in Nursing from Virginia Commonwealth University. She graduated with a Doctorate in Nursing Practice from the University of Virginia in 2018. Her research interests include portal hypertension and liver transplantation. She is the Clinical Program Manager for Hepatology and Liver Transplant at the McGuire Veterans Affairs Medical Center in Richmond, Virginia.

    Dr. Gilles is actively engaged in professional organizations including the American Association of the Study of Liver Diseases (AASLD). She was the immediate past Chair of the Hepatology Associates Committee is the Chair of the Hepatology Associates Special Interest Group. HoChong currently serves as the President of the Virginia Council of Nurse Practitioners.

  • Alcoholic Liver Disease and Public Health/Health Care Delivery SIGs: Alcoholic Liver Disease: Policy & Practice

    Contains 8 Component(s) Recorded On: 11/11/2018

    AASLD's Alcoholic Liver Disease SIG presented at The Liver Meeting® 2018.

    This program will provide practicing clinicians with an update on recent changes in the epidemiology of alcoholic liver disease, advances in understanding of its pathophysiology and the impact of social policies on alcohol use disorders. The program will then present advances in the treatment of alcohol abuse and alcoholic liver disease, including novel models of multidisciplinary care for these patients.

    Jessica L. Mellinger

    Ian Gilmore

    Robert Weinrieb

    Vijay Shah

  • Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture

    Contains 1 Component(s) Recorded On: 11/11/2018

    AASLD'S Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture presented at The Liver Meeting® 2018.

    This lecture will examine the intersection of hepatobiliary neoplasia and liver transplantation to highlight what is currently working well, including liver transplantation for early stage hepatocellular carcinoma and hilar cholangiocarcinoma, as well as less common indications such as euroendocrine tumors. The speaker will highlight continued challenges, particularly related to overall disease burden, organ availability and allocation policy, and transplantation for more advanced tumors. A discussion of future challenges will explore opportunities for a multi-disciplinary approach using novel systemic therapies that are becoming available for advanced liver disease and advanced malignancy.

    Julie Heimbach

  • Hans Popper Basic Science State-of-the-Art Lecture

    Contains 1 Component(s) Recorded On: 11/11/2018

    AASLD's Hans Popper Basic Science State-of-the-Art Lecture presented at The Liver Meeting® 2018.

    Hans Clevers, MD, PhD, will describe his groundbreaking research in the development of organoid technology and how it can be applied to liver and biliary disease. His lecture will focus on organoids developed from bile duct cells and hepatocytes, and applications for disease modeling in cancer, hereditary disease and regenerative medicine strategies.

    Hans Clevers

  • 2018 Postgraduate Course: A Hectic Day for a Hepatology Consultant

    Contains 24 Component(s), Includes Credits Recorded On: 11/10/2018

    AASLD's 2018 Postgraduate Course: A Hectic Day for a Hepatology Consultant presented at The Liver Meeting® 2018.

    The practice of Hepatology is largely consultative in nature, whether evaluating outpatients referred for a variety of abnormal liver enzyme findings or diagnosing and managing critically-ill patients within a team of internists, hospitalists, residents, intensivists, and other healthcare providers.  On any given day, a hepatologist will be confronted with complex patients and dizzying differential diagnoses to be methodically considered.  The aim of this course is to provide insights about state-of-the-art consultative Hepatology attendees that can be applied to daily practice.


    2018 Postgraduate Course Enduring Release Dates:

    • The Liver Meeting® 2018 Attendees: Immediately following The Liver Meeting®
    • AASLD Members: February 1, 2019
    • LiverLearning® Subscribers: March 1, 2019

    Core Competencies:   

    • Patient-centered Care
    • Medical Knowledge
    • Practice Based Learning and Improvement 
    • Interpersonal and Communication Skills
    • Professionalism
    • Work in Interdisciplinary Teams
    • Employ Evidence-based Practice
    • Roles/Responsibilities
    • Interprofessional Communication
    • Teams and Teamwork

    Speakers

    • Michael W. Fried, MD, FAASLD (Program Chair)
    • Cynthia Levy, MD, FAASLD (Program Chair)
    • Tse-Ling Fong, MD, FAASLD (Program Chair)
    • Naga P. Chalasani, MD, FAASLD (Moderator)
    • Rohit Loomba, MD (Moderator)
    • Alfred Sidney Barritt, MD, MSCR
    • Michael P. Manns, MD
    • Heiner Wedemeyer, MD
    • Mandana Khalili, MD
    • Guadalupe Garcia-Tsao, MD, FAASLD (Moderator)
    • Oren K. Fix, MD, MSc, FAASLD (Moderator)
    • Kymberly Watt, MD
    • Andres Cardenas, MD, MMSc, PhD, FAASLD
    • Steven L. Flamm, MD
    • Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD
    • Vijay Shah, MD
    • Laura M. Kulik, MD (Moderator)
    • K. Rajender Reddy, MD, FAASLD (Moderator)
    • Christopher L. Bowlus, MD, FAASLD
    • Paul Y. Kwo, MD, FAASLD
    • Lewis R. Roberts, MBChB, PhD, FAASLD
    • Paul C. Adams, MD, FAASLD
    • Mindie H. Nguyen, MD, MAS, FAASLD
    • Robert S. Brown, MD, MPH, FAASLD (Moderator)
    • Estella M. Alonso, MD, FAASLD (Moderator)
    • Nancy Reau, MD, FAASLD
    • Keyur Patel, MD
    • Michael B. Fallon, MD, FAASLD
    • Elizabeth Rand, MD
    • Patrick S. Kamath, MD

    Copyright: All faculty in this activity have given their permission for publication OR ©2018 AASLD

    The 2018 Postgraduate Course: A Hectic Day for a Hepatology Consultant currently does not offer CME, CE or MOC. The live course activity to claim CME and MOC ended Friday, March 15, 2019. This unit is available for viewing purposes only. Check back for updates!

    Alfred Sidney Barritt

    Michael P. Manns

    Heiner Wedemeyer

    Mandana Khalili

    Kymberly Watt

    Andres Cardenas

    Dr. Andrés Cárdenas is currently a Consultant and Clinical Professor of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and University of Barcelona. During his residency in Internal Medicine at Boston University Medical Center, he became interested in advanced liver disease, further pursuing a Research Fellowship in Hepatology for 2 years at Hospital Clinic and University of Barcelona in Spain. He returned to Harvard Medical School and BIDMC for his Clinical Fellowship in Gastroenterology and Hepatology. Dr. Cárdenas is Board Certified in Internal Medicine, Gastroenterology and Hepatology by the American Board of Internal Medicine. His main expertise and research interests are complications of cirrhosis, interventional procedures in patients with cirrhosis and portal hypertension and biliary complications in liver transplant recipients.

    Steven L. Flamm

    Rajiv Jalan

    Vijay Shah

    Christopher L. Bowlus

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Paul Y. Kwo

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

    Lewis R. Roberts

    Dr. Lewis R. Roberts is the Peter and Frances Georgeson Professor in Gastroenterology Cancer Research and a Consultant in the Division of Gastroenterology and Hepatology at the Mayo Clinic, where he is Director of the Hepatobiliary Neoplasia Clinic, Co-Chair of the Hepatobiliary Cancer Disease Group of Mayo Clinic Cancer Center, Co-Principal Investigator of the Mayo Specialized Program of Research Excellence (SPORE) in Hepatobiliary Cancers, Associate Director of Pre-Doctoral Programs in the Center for Clinical and Translational Sciences, and Director for Research at Mayo Clinic Alix School of Medicine. Dr. Roberts earned his medical degree from the University of Ghana Medical School, a PhD in Physiology and Biophysics from The University of Iowa, and completed postgraduate training in Internal Medicine, Gastroenterology and Hepatology, and Cancer Genetics at Mayo Clinic.

    Dr. Roberts clinical practice is focused on liver and biliary cancers. His research includes studies of the mechanisms of liver and biliary carcinogenesis; biomarkers to improve the diagnosis of liver, bile duct and pancreas cancers; and prevention, diagnosis and treatment of hepatitis and liver cancer. His research has been funded by NIH, The Robert Wood Johnson Foundation, the AGA Foundation, and The Cholangiocarcinoma Foundation. He has authored over 300 publications.

    Dr. Roberts currently serves as Deputy Editor of HEPATOLOGY and is on the Editorial Boards of Liver Cancer and Hepatic Oncology.

    Mindie H. Nguyen

    Dr. Nguyen is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Nancy S. Reau

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Keyur Patel

    Michael B. Fallon

    Elizabeth Rand

    Patrick S. Kamath

    Session I: Morning Routine

    MODERATORS: Naga P. Chalasani, MD, FAASLD and Rohit Loomba, MD

    8:00 - 8:10 AM                                                                   A Hectic Day in the Life of a Hepatology Consultant

                                                                                                    Welcome/Qualities of a Valued Consultant

    8:10 - 8:30 AM                                                                   Abnormal Liver Enzymes in a Patient with Diabetes

                                                                                                    Alfred Sidney Barritt, MD, MSCR

    8:30- 8:50 AM                                                                    Hepatitis C in a 23-year-old who Injects Drugs

                                                                                                    Michael P. Manns, MD

    8:50 - 9:10 AM                                                                   Abnormal Liver Enzymes and Recurrent UTI in a 67-year-old Woman

                                                                                                    Heiner Wedemeyer, MD

    9:10 – 9:30 am                                                                  HBV/HCV Coinfection in a Pregnant Woman

                                                                                                    Mandana Khalili, MD

    9:30 – 9:50 am                                                                  Break

    Session II: Rounds in the MICU

    MODERATORS: Guadalupe Garcia-Tsao, MD, FAASLD and Oren K. Fix, MD, MSc, FAASLD 

    9:50 - 10:10 AM                                                                Fever and Elevated Liver Enzymes in a Liver Transplant Recipient

                                                                                                    Kymberly Watt, MD

    10:10 - 10:30 AM                                                              Massive GI Bleeding in a Patient with Cirrhosis: What’s New?

                                                                                                    Andres Cardenas, MD, MMSc, PhD, FAASLD

    10:30 - 10:50 AM                                                              Altered Mental Status in a Patient with Refractory Ascites

                                                                                                    Steven L. Flamm, MD

    10:50 – 11:10 AM                                                             Acute Liver Failure in a 26-year-old Woman

                                                                                                    Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD

    11:10 - 11:30 AM                                                              Jaundice and Renal Failure in a Patient with Alcoholic Cirrhosis

                                                                                                    Vijay Shah, MD

    11:30 - 11:40 AM                                                              Break

    11:40 - 1:05 PM                                                                Intermission/Meet-the-Professor Luncheons

    Session III: Meanwhile, Back in the Office…

    MODERATORS: Laura M. Kulik, MD and K. Rajender Reddy, MD, FAASLD

    1:05 - 1:25 PM                                                                   Cholestatic Liver Abnormalities in a 52-year-old African American Woman

                                                                                                    Christopher L. Bowlus, MD, FAASLD

    1:25 – 1:45 pm                                                                  Multiple Liver Masses in a 42-year-old Woman Advances in the Diagnosis of Hepatobiliary Neoplasia

                                                                                                    Paul Y. Kwo, MD, FAASLD

    1:45 – 2:05 pm                                                                  A 1.9 cm HCC in a Patient with HCV Cirrhosis

                                                                                                    Lewis R. Roberts, MBChB, PhD, FAASLD

    2:05 – 2:25 pm                                                                  “My Brother Was Just Told He Had Too Much Iron in His Blood”

                                                                                                    Paul C. Adams, MD, FAASLD

    2:25 – 2:45 pm                                                                  A Patient with Crohn’s Disease and HBcAb+

                                                                                                    Mindie H. Nguyen, MD, MAS, FAASLD

    2:45 – 3:05 pm                                                                  Break

    Session IV: Exploring Other Units at Dusk

    MODERATORS: Robert S. Brown, MD, MPH, FAASLD and Estella M. Alonso, MD, FAASLD

    3:05 – 3:25 pm                                                                  Hyperbilirubinemia in Labor and Delivery

                                                                                                    Nancy Reau, MD, FAASLD

    3:25 – 3:45 pm                                                                  Hyperbilirubinemia in a Patient after Bone Marrow Transplant

                                                                                                    Keyur Patel, MD

    3:45 – 4:05 pm                                                                  A 60-year-old in CCU with Jaundice

                                                                                                    Michael B. Fallon, MD, FAASLD

    4:05 – 4:25 pm                                                                  A 14-year-old Child s/p Fontan Procedure with Liver Abnormalities

                                                                                                    Elizabeth Rand, MD

    4:25 – 4:45 pm                                                                  Acute Right Upper Quadrant Pain in a Patient with Cirrhosis

                                                                                                    Patrick S. Kamath, MD

    4:45 – 5:00 pm                                                                 Wrap Up

    Upon completion of this activity, participants will be able to:

    • Differentiate presentations of complex liver diseases across different patient populations
    • Apply best practices to diagnose and manage inpatients and outpatients with complex liver disease
    • Communicate therapeutic recommendations to multiple healthcare providers encompassing the extended care team

    Hepatologists   

    Gastroenterologists       

    Nurses

    Nurse Practitioners        

    Pharmacists

    Physician Assistants       

    Transplant Coordinators

    Surgeons            

    Fellows/Trainees

    Satisfactory completion 

    Participants must pass a post-test with a score of 70% or higher and complete an evaluation to receive a certificate of completion.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.   

    CME 

    Accreditation Statement The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation AASLD designates this enduring activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Maintenance of Certification

    American Board of Internal Medicine (ABIM) MOC Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    American Board of Pediatrics (ABP) MOC Statement

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participation and feedback to the participant, enables the participant to earn 6 MOC points in the American Board of Pediatrics (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    MOC Points Process 

    • Physicians seeking MOC points must complete the CME evaluation in addition to viewing all of the presentation(s) and successfully passing the post-test(s) for each module with a score of 70% or better. MOC completions are collected on the 15th of each month and submitted to the ABIM and/or ABP by the last day of the month.
    • Claiming of CME credits for the live course can be completed via The Liver Meeting® app or on AASLD's online CME claiming page.
    • To claim MOC for attending the live 2018 Postgraduate Course, please visit the 2018 Postgraduate Course MOC activity.

    Faculty, Planner and AASLD Staff Disclosures

    This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Postgraduate Course faculty and the following planning committees: AASLD Education Committee, Scientific Program Committee, and the Governing Board.

    As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months.  A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.  All conflicts of interest are resolved prior to participation.

    Statement on off-label and investigational use: Speakers are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below:

    Postgraduate Course Faculty Disclosures

    Paul C. Adams, MD, FAASLD

    Consulting: Protagonist Therapeutics

    Alfred Sidney Barritt IV, MD, MSCR

    Advisory Committee or Review Panel: Target Pharmasolutions

    Consulting: Dova Pharmaceuticals

    Speaking and Teaching: SC Liver Research Consortium

    Christopher L Bowlus, MD, FAASLD

    Advisory Committee or Review Panel: BMS, Contatus, Cymabay

    Consulting: Eli Lilly, BiomX

    Grant/Research Support: TARGET Pharmasolutions, JKB Taiwan, Genkyotex, Takeda, Allergan, GSK, Arena, Gilead, Cymabay, Intercept Pharmaceuticals, Novartis, Eli Lilly

    Andres Cardenas, MD, MMSc, PhD, FAASLD

    Board Membership: Liver Transplantation Journal

    Consulting: UptoDate

    Grant/Research Support: Boston Scientifi

    Michael B. Fallon, MD, FAASLD

    Nothing to Disclose

    Steven L. Flamm, MD

    Consulting: Gilead, Abbvie, Merck, Salix, Intercept, Dova, Shonogi

    Grant/Research Support: Gilead, Abbvie, Intercept

    Rajiv Jalan, MD, PhD, FRCP, FRCPE, FAASLD

    Consulting: Yaqrt Ltd

    Grant/Research Support: Ocera Therapeutics Inc.

    Patrick S Kamath, MD

    Nothing to Disclose

    Mandana Khalili, MD

    Grant/Research Support: Gilead Sciences, Intercept Pharmaceuticals

    Paul Yien Kwo, MD, FAASLD

    Advisory Committee or Review Panel: Abbvie, BMS, Gilead, Merck, Shionogi, Dova, Durect, Janssen

    Grant/Research Support: Abbvie, Gilead, Aurora, La Jolla Pharmaceuticals

    Speaking and Teaching: Merck

    Stock Shareholder: Durect

    Michael P. Manns, MD

    Advisory Committee or Review Panel: MSD - Merck Sharp & Dome, Abbvie, Novartis, Gilead, Bristol-MyersSquibb

    Consulting: AbbVie, Gilead, Curevac, Eiger, Enyo Pharma, Falk Foundation, Intercept, Janssen, Medgenics, MSD - Merck, Novartis, GedeonRichter, Roche, Allergan, Preglem

    Grant/Research Support: AbbVie, Gilead, Eiger, Intercept, J

    Mindie H. Nguyen, MD, MAS, FAASLD

    Advisory Committee or Review Panel: Gilead

    Consulting: Spring Bank, Norvatis

    Grant/Research Support: Gilead, B K Kee Foundation, NCI

    Keyur Patel, MD

    Advisory Committee or Review Panel: Gilead Sciences, Merck

    Elizabeth Rand

    Nothing to Disclose

    Nancy Reau, MD, FAASLD

    Nothing to Disclose

    Lewis R. Roberts, MBChB, PhD, FAASLD

    Advisory Committee or Review Panel: Bayer, Exact Sciences, TAVEC, Inc

    Grant/Research Support: Gilead Sciences, Wake Diagnostics, Ariad Pharmaceuticals, BTG International, RedHill BioPharma

    Vijay Shah, MD

    Advisory Committee or Review Panel: Novartis Pharmaceuticals, Merck Research Laboratories, Afimmune, Ltd, Durect Corporation

    Kymberly Watt, MD

    Grant/Research Support: Gilead, Intercept

    Heiner Wedemeyer, MD

    Advisory Committee or Review Panel: Norgine, MSD, Janssen, Roche Diagnostic

    Board Membership: Abbvie, Gilead

    Consulting: Abbott, BMS, Eiger, MyrGmbH

    Grant/Research Support: Abbott, BMS, Gilead, Roche Diagnsotics

    Speaking and Teaching: Abbvie, Abbott, BMS, Gilead, Falk, Norgine, MSD

    Planner Disclosures

    Gavin E. Arteel, PhD, FAASLD (Scientific Program Committee)

    Nothing to Disclose

    Gyorgy Baffy, MD, PhD, FAASLD (Education Committee)

    Nothing to Disclose

    Jasmohan S. Bajaj, MD, MSc, FAASLD (Education Committee)

    Consulting: Valeant, Norgine, and Abbott

    Grant/Research Support: Salix, Grifols

    Ramon Bataller, MD, PhD (Education Committee)

    Speaking and Teaching: Echosens

    Alex Befeler, MD (Scientific Program Committee)

    Advisory Committees or Review Panels: Bayer, Gilead

    Grant/Research Support: Mallinckrodt, Sillajen

    Stock Shareholder: Amgen, Gilead

    Jorge A. Bezerra, MD, FAASLD (Education Committee and Governing Board)

    Grant/Research Support: Gilead, Molecular Genetics Laboratory, CHMC, Shier

    Kyle E. Brown, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Kimberly A. Brown, MD, FAASLD (Governing Board and Scientific Program Committee)

    Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb, CLDF, Gilead, Janssen, Merck

    Grant/Research Support: AbbVie, Duke medical research, Gilead, Janssen, Merck, Novartix

    Speaking and Teaching: CLDF

    Elizabeth M. Brunt, MD, FAASLD (Education Committee)

    Advisory Committees or Review Panels: Gilead

    Andres Cardenas, MD, PhD, FAASLD (Education Committee)

    Advisory Committees or Review Panels: Gilead

    Amanda J. Chaney, DNP, ARNP, FNP-BC (Education Committee)

    Nothing to Disclose

    Raymond T. Chung, MD, FAASLD (Governing Board)

    Advisory Committees or Review Panels: Alnylam

    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Janssen, Merck

    Mark J. Czaja, MD, FAASLD (Governing Board)

    Consulting: Verlyx Pharma Inc.

    Michael W. Fried, MD, FAASLD (Governing Board and Scientific Program Committee)

    Consulting: AbbVie, Bristol-Myers Squibb, Gilead, Merck, TARGET PharmaSolutions

    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead, Merck

    Stock Shareholder: TARGET PharmaSolutions

    Julie Heimbach, MD, FAASLD (Governing Board)

    Nothing to Disclose

    Patrick M. Horne, MSN, ARNP, FNP-BC (Scientific Program Committee)

    Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb, Chronic Liver Disease Foundation, Gilead Sciences, Merck

    Wikrom Karnsakul, MD (Education Committee)

    Nothing to Disclose

    Andrew P. Keaveny, MD, FAASLD (Education Committee and Scientific Program Committee)

    Independent Contractor: UpToDate Inc

    Cynthia Levy, MD (Scientific Program Committee)

    Advisory Committees or Review Panels: Target Pharmasolutions

    Board Membership: Liver Transplantation

    Consulting: Intercept, Novartis

    Grant/Research Support: CymaBay, Gilead, Intercept, NGM, Novartis, Tobira

    Speaking and Teaching: Medscape

    Keith D. Lindor, MD, FAASLD (Governing Board)

    Advisory Committees or Review Panels:  Intercept, Shire

    Anna S. Lok, MD, FAASLD (Governing Board and Scientific Program Committee)

    Grant/Research Support: Bristol-Myers Squibb, Gilead, Target Solutions

    Bruce A Luxon, MD, PhD, FAASLD (Governing Board)

    Nothing to Disclose

    John C. Magee, MD (Scientific Program Committee)

    Nothing to Disclose

    Mitchell A. Mah'moud, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Richard A. Manch, MD, FAASLD (Education Committee)

    Speaking and Teaching:  Salix, Bayer, Gilead, AbbVie, Intecept

    Lopa Mishra, MD, FAASLD (Governing Board)

    Nothing to Disclose

    David C. Mulligan, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Mary K. Panther, BSN, RN, CGRN (Education Committee)

    Stock Shareholder: Merck

    K. Gautham Reddy, MD, FAASLD (Scientific Program Committee)

    Advisory Committees or Review Panels: Gilead, Intercept

    Grant/Research Support: Genfit, Intercept, Merck

    Speaking and Teaching: Intercept

    Ronald J. Sokol, MD, FAASLD (Governing Board and Scientific Program Committee)

    Consulting: Alexion, Alnylam, Retrophin

    Grant/Research Support: FFF Enterprises, Giliad, Shire/Lumena

    Grace L. Su, MD, FAASLD (Education Committee)

    Nothing to Disclose

    Ayako Suzuki, MD, PhD, MSc (Education Committee)

    Nothing to Disclose

    Lisa B. VanWagner, MD, MSc (Education Committee)

    Grant/Research Support: Novartis

    Speaking and Teaching: Salix

    Steven A. Weinman, MD, PhD, FAASLD (Education Committee)

    Nothing to Disclose

    Maria L. Yataco, MD (Education Committee)

    Grant/Research Support: Genfit/Intercept

    AASLD Staff Disclosures

    Amy D'Amato

    Nothing to Disclose

    Katie Duggan

    Nothing to Disclose

    Steven Echard, IOM, CAE

    Nothing to Disclose

    Stephanie Grimsby

    Nothing to Disclose

    Jessica Jessop

    Nothing to Disclose

    Janeil C. Klett

    Nothing to Disclose

    Denise Seise

    Nothing to Disclose  

  • Cholestatic and Autoimmune Diseases SIG: Advancing AIH Understanding and Care

    Contains 9 Component(s) Recorded On: 11/09/2018

    AASLD's Cholestatic and Autoimmune Diseases SIG: Advancing AIH Understanding and Care presented at The Liver Meeting® 2018.

    This program presents an update on the current state of knowledge about autoimmune hepatitis and identify the gaps in knowledge related to the immunologic, environmental, and genetic factors underlying AIH. The program will also review clinical management, identify unmet needs, and discuss barriers along the path toward development of new therapies for AIH.

    Christopher L. Bowlus (Moderator)

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Luca Fabris (Moderator)

    David Assis

    Craig Lammert

    Nanda Kerkar

    Dermot Gleeson

    Christoph Schramm

  • Hepatitis C SIG: Navigating the road to elimination of HCV in the U.S.

    Product not yet rated Contains 9 Component(s) Recorded On: 11/09/2018

    AASLD's Hepatitis C SIG: Navigating the road to elimination of HCV in the U.S. presented at The Liver Meeting® 2018.

    This program covers the key components that support efforts to define a program toward eradication of HCV in the U.S.  The program is centered around modeling, engagement of individuals difficult to link to care and screening efforts.  Access to care and the role of advocacy is instrumental and approaches toward successful advocacy will also be discussed.  

    John W. Ward

    Anne Spaulding

    Jason Grebely

    Nancy S. Reau (Moderator)

    Dr. Nancy Reau is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center. Dr Reau’s research interest is in viral hepatitis drug development as well as utilisation. She has authored or co-authored over 100 peer-reviewed articles, invited reviews, editorials and online programmes, as well as several book chapters, and two books. She is the editor in chief for Clinical Liver Disease, the AASLD multimedia journal.  She was one of the original authors of the AASLD/IDSA hepatitis C guidance document.  She is currently a member of the steering committee for the hepatitis C special interest group for the AASLD and is a member of the gastroenterology writing committee for the American Board of Internal Medicine.

     

    Stacey Trooskin

    Stacey Trooskin, MD PhD, is the Director of Viral Hepatitis Programs at Philadelphia FIGHT Community Health Centers and Clinical Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania.  She received her MPH from Yale University School of Public Health, her medical degree from Robert Wood Johnson Medical School, and her PhD from Rutgers School of Public Health. She completed her internal medicine residency and infectious diseases fellowship at the Hospital of the University of Pennsylvania.

    Dr. Trooskin’s primary research interest focuses on health disparities and developing and evaluating innovative models of HCV testing and linkage to care. Dr. Trooskin serves at the Chief Medical Advisor to the National Viral Hepatitis Roundtable and is a member of the AASLD/IDSA HCV Guidelines Committee.  She is the Community Co-chair of the Hepatitis C Allies of Philadelphia (HepCAP) and the Principal Investigator of C Change: Philadelphia’s Plan to End Hepatitis C Among People Who Inject Drugs.

    Michael Ninburg

    Robert G. Gish

    Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.

    Andrew J. Muir (Moderator)

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

  • Clinical Research Workshop: Researching and Applying Precision Medicine in Hepatology

    Contains 7 Component(s) Recorded On: 11/09/2018

    AASLD's Clinical Research Workshop: Researching and Applying Precision Medicine in Hepatology presented at The Liver Meeting® 2018.

    Precision medicine has the potential to completely revolutionize health care research and treatment – allowing doctors and researchers to more accurately predict which treatment and prevention strategies for a particular disease will work in individual patients or groups of patients vs. a one-size-fits all paradigm. This workshop will describe the importance of genomic and other molecular information to the delivery of individualized clinical care and identify challenges to implementation, help attendees associate clinically available tools in the diagnosis and management of chronic liver disease with emerging technology, illustrate a clear example of the utility and limitations of precision medicine approaches in hepatology and identify available resources to overcome limitations.

    David Goldstein

    Nancy Spinner

    Grace Su

    Yujin Hoshida

    Julia Wattacheril

    Louise Bier